It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...

Boehringer Ingelheim reported positive growth in the first half of 2025, with group net sales growing by 6.3%* to EUR 14.0 billion.

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.